According to the latest filings with the SEC, company insiders at Calithera Biosciences, Inc. (NASDAQ:CALA) have increased their position in the stock by 28.61% over the past 6 months. Insiders now own 6.30% of total outstanding shares.
University of Michigan professor and noted insider trading researcher discovered that when insiders bought shares of their own companies, the stocks outperformed the total market by 8.9% over the next 12-month period. When they sold shares, the stock underperformed 5.4%.
Calithera Biosciences, Inc. (NASDAQ:CALA) stands 7.37% away from its 50-day simple moving average and also 89.33% away from the 200-day average. Recently, the equity stands -19.49% away from the 52-week high and 547.73% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 48.60.
Wall Street analysts on the sell-side covering shares of Calithera Biosciences, Inc. (NASDAQ:CALA) have a mean recommendation of 1.80 on the shares. This is based on a numerical chart where each stock recommendation (Buy,Sell,Hold) is translated into a numerical equivalent. A low number indicates a Buy and a higher number a Sell. In terms of where analysts see the stock headed, they have a consensus price target of $17.60 on the shares.